By staff writers

October 21, 2019 -- A low-cost investigational technique for assessing copy number alterations helps identify cancers that are aggressive, enabling clinicians to guide treatment accordingly, researchers at the Karolinska Institutet in Sweden reported in Nature Communications online October 18.

Senior researchers Magda Bienko, PhD, and Nicola Crosetto, PhD, and colleagues described the use of the technique -- dubbed CUTseq -- for low-cost measurement of copy number alterations throughout a tumor. Tumors with many copy number alterations are known to be aggressive with a higher risk of relapse for patients, who consequently require more aggressive treatment strategies.

The technique was developed as a way of overcoming limitations of next-generation sequencing technologies that are widely available but, nevertheless, are often still out of reach, the authors wrote. Although there are many ways to prepare DNA libraries and the cost of sequencing has dropped in the last decade, sequencing of multiple samples in parallel is still very expensive due to the methods for multiplexing, they explained.

"Typically, this is done by indexing libraries prepared from individual samples, followed by pooling together multiple libraries in the same sequencing run," the group wrote. "This means that all the steps in the library preparation procedure must be repeated for every sample to be sequenced, which is labor-intensive and multiplies the cost of reagents."

The Karolinska team overcame these barriers and achieved multiplexing by directly barcoding genomic DNA, prior to building a library, and then pooling barcoded samples into a single library. This enables high levels of multiplexing but at a low cost, according to the researchers.

CUTseq was a sensitive and reproducible method in cell lines and formalin-fixed paraffin embedded (FFPE) tissues in primary and metastatic breast cancer, they found. Using single FFPE tumor sections, they were able to profile copy number alterations in heterogeneous tumors at high spatial resolution. The technique can be used in nonfixed and fixed samples, the authors wrote.

The study provides proof-of-principle evidence for the method, they concluded.

"Overall, these results demonstrate that CUTseq is a robust and sensitive method that can be used to profile, at high spatial resolution, DNA [copy number alterations] across multiple regions in clinically relevant tumor samples, thus providing valuable insights into intratumor genetic heterogeneity," the researchers wrote.

Furthermore, the technique is versatile and could be applied in many different ways in research and diagnostics -- beyond cancer, they concluded.

Grail builds case for multicancer blood test
Grail released a new analysis of data supporting its multicancer blood test in a late-breaking oral presentation at the European Society for Medical Oncology...
ESMO: Roche's blood-first screening plan passes go in lung cancer
Blood-based next-generation sequencing for identifying ALK genetic mutations and guiding drug treatment accordingly was validated in Roche's BFAST study...
ESMO: Blood test predicts relapse risk in colon cancer
A blood test showed potential for predicting relapse in nonmetastatic colon cancer patients and for reducing unnecessary treatments in a large study reported...
Bluestar bolsters blood test with breast, pancreatic cancer data
Bluestar Genomics presented data supporting its cell-free epigenomic approach to liquid biopsies in breast and pancreatic cancer during the National Cancer...

Copyright © 2019

Last Updated np 10/18/2019 4:38:41 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.